Press Releases

Allos Pharma Inc. a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has held a meeting with the U.S. Food and Drug Administration (FDA) to optimize the design of their Phase 3 trial. This trial is designed to support a New Drug Application (NDA) to address Fragile X Syndrome, for which there is no approved medicine today. Allos' investigational drug, arbaclofen, targets the molecular pathophysiology

Rocket Pharmaceuticals, Inc. a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L301, the Company’s investigational lentiviral-based gene therapy for Pyruvate Kinase Deficiency (PKD), a rare blood disorder characterized by severe anemia and excess

Croda Pharma and BSI announced that they have entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutical grade adjuvant QS-21, a potent component of adjuvant systems. QS-21 is used in several innovative vaccines against diseases such as shingles, malaria and RSV, plus promising new vaccine and immunotherapy treatments such as cancer. This partnership sees the two organisations share expertise to bring to market QS-21 from Quillaja saponari

Complying to ever evolving global requirements of emerging markets and meeting regulatory expectations of a well evolved landscape is vital to maintain the safety & efficacy of the new & existing drugs, and accuracy of product information. Eminence Business Media acknowledges this need and after conducting several successful conferences, liked, and appreciated by the pharma fraternity, we are coming up with the inaugural program Pharma Regulatory Conclave 2023 in Hilton, Goa.

Ironwood Pharmaceuticals, Inc. a GI-focused healthcare company, and VectivBio Holding AG  a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion, net of VectivBio cash and debt (the “Trans

Yaral Pharma Inc., the United States generics subsidiary of IBSA  today announced its expanding partnership with EVERSANA®, a leading provider of commercialization services to the global life sciences industry, as its key commercialization partner to support the expansion of its portfolio of pain and endocrinology products in the U.S. EVERSANA will provide a full range of services including, but not limited to, third-party logistics (3PL) and critical operations support to ensure bes

OmicsEdge has launched an industry leading drug discovery service that leverages Almaden’s g.nome™ platform to streamline the iteration process. The service makes it easy for labs to conduct a quick analysis of a patient or trial participant’s medical condition and genomics, gaining valuable insight in genomic criteria and how it affects elevated risk. The service can be used to significantly accelerate the drug discovery process and eliminate trial-and-error with abilities

The influential Pharmapack Awards 2024 are open for submissions (entry deadline 31st August, 2023) with two new categories and eight prizes in total – divided into two separate streams for Exhibitor Innovation Awards and the Health Product Awards. The Exhibitor Innovation Awards celebrate ‘new concepts in packaging materials, including primary or secondary packaging, cool chain and logistics, start-ups, and drug delivery solutions’, while the Health Product Awards

Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues t

Roche announced today positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclero The study met its primary and secondary endpoints, showing oral fenebrutinib significantly reduced magnetic resonance imaging (MRI) markers of MS disease activity in the brain compared to placebo. Additionally, pre-clinical data have shown fenebrutinib to be potent and highly selective, and it is the only reversible inhibitor cur